title: Serum MMP-9 activity as a diagnosing marker for the developing heart failure of post MI patients.
abstract: Myocardial infarction (MI) is the result, in mostly cases, of the destabilization and rupture of atherosclerotic lesions. The destruction of cardiac tissue resulting from myocardial ischemia could further result in heart failure. It has been suggested that plaque instability may be mediated by matrix metalloproteinase (MMP) family. Studies have identified increased MMP-2 and MMP-9 in human platelets, and acute myocardial infarction patients with elevated MMP-2 and MMP-9 levels. However, the alteration of MMP-2 and MMP-9 from post MI left ventricle remodeling to heart failure remains to be clarified. The purpose of this study is to investigate the serum concentrations and activities of MMP-2 and MMP-9 in the developing heart failure from post MI patients. Twenty eight patients with MI without heart failure (Killip FC I) (group A; compensated) and twenty seven MI patients with heart failure (Killip II-III) (group B; decompensated) were collected to evaluate the serum levels and activities of MMP-2 and MMP-9 by ELISA and Zymography, respectively. It was observed that the both serum levels and activities of MMP-9 significantly increased (P < 0.01) in decompensated group compared to compensated group, but there was no significant difference of serum MMP-2 levels and activities between two groups. The highly elevated serum MMP-9 concentration of decompensated patients is not related with inflammatory or localized infarct area of myocardium and the real mechanisms remain to be revealed. We suggest that the increase of MMP-9 levels and activity may be used as a new marker to diagnose the development of heart failure in patients with post MI, and provide the therapeutic implications in the future.
authors.affiliation: Division of Cardiology, Armed Force Taichung General Hospital, Taichung, Taiwan, ROC.
authors.forename: Gwo-Ping
authors.initials: GP
authors.lastname: Jong
authors.forename: Tsochiang
authors.initials: T
authors.lastname: Ma
authors.forename: Pesus
authors.initials: P
authors.lastname: Chou
authors.forename: Mu-Hsin
authors.initials: MH
authors.lastname: Chang
authors.forename: Chieh-His
authors.initials: CH
authors.lastname: Wu
authors.forename: Ping-Chun
authors.initials: PC
authors.lastname: Lis
authors.forename: Shin-Da
authors.initials: SD
authors.lastname: Lee
authors.forename: Jer-Yuh
authors.initials: JY
authors.lastname: Liu
authors.forename: Wei-Wen
authors.initials: WW
authors.lastname: Kuo
authors.forename: Chih-Yang
authors.initials: CY
authors.lastname: Huang
mesh_terms: D015415:Biomarkers / Q000097:blood; D004789:Enzyme Activation; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000175:diagnosis*; D017063:Outcome Assessment, Health Care / Q000379:methods; D011379:Prognosis; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D020780:Matrix Metalloproteinase 9